23:59 , Jun 21, 2018 |  BC Innovations  |  Product R&D

Tusk’s take on CD25

As companies revisit the potential of IL-2 to aid cancer immunotherapy, Tusk Therapeutics Ltd. has a new take by attacking CD25, a component of the IL-2 receptor with its own storied past. Its antibody could...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
19:20 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

ADC Therapeutics discontinues HER2 program

ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug conjugate (ADC) in patients with HER2-expressing advanced solid tumors did not show "sufficient patient benefit to justify further development."...
18:51 , Apr 25, 2018 |  BC Extra  |  Clinical News

ADC Therapeutics discontinues HER2 program

ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug conjugate (ADC) in patients with HER2-expressing advanced solid tumors did not show "sufficient patient benefit to justify further development."...
21:55 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

ADC reports Phase I data for ADCT-301 in Hodgkin's lymphoma

ADC Therapeutics S.A. (Epalinges, Switzerland) reported interim data from 35 evaluable patients with Hodgkin's lymphoma in a Phase I trial showing that IV ADCT-301 (camidanlumab tesirine, Cami-T, HuMax-TAC-ADC) led to an overall response rate (ORR)...
21:54 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

ADC reports Phase I data for ADCT-402 in NHL

ADC Therapeutics S.A. (Epalinges, Switzerland) reported interim data from 68 evaluable patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) in the dose-escalation portion of the Phase I ADCT-402-101 trial showing that IV ADCT-402...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
19:02 , Oct 27, 2017 |  BC Week In Review  |  Financial News

ADC raises $200M private placement

On Oct. 23, antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN). Next year, ADC...
22:06 , Oct 26, 2017 |  BioCentury  |  Finance

Pays to stay private

While ADC Therapeutics S.A. has the hallmarks of a biotech ready for the public markets, the Swiss cancer company decided to stay private with its latest financing, citing the relative cost of capital. The oversubscribed...
09:25 , Oct 23, 2017 |  BC Extra  |  Financial News

ADC Therapeutics raises $200M

Antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN). Next year, ADC Therapeutics plans to...